useful in cases in which coughing or other factors might affect PFT performance or interpretation, when changes in symptoms or PFT results lead to uncertainty about whether there has been ILD progression, when there is concern for infection or malignancy, or when assessing treatment response. For people with SARD-ILD, we suggest monitoring for ambulatory desaturation every 3 to 12 months. There was a discrepancy between the application of this clinical assessment by rheumatologists and